Bone And Connective Tissue Cancer

Nirogacestat Gets Fast-Tracked for the Treatment of Desmoid Tumors

By November 08, 2018

The Company is planning a Phase 3 study (DeFi) sometime in the first half of 2019.

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma

November 08, 2018

The researchers found that median progression-free survival was 10.3 and 4.7 months in the elotuzumab and control groups, respectively, after a minimum follow-up period of 9.1 months.

New Formulation of Levoleucovorin Gets FDA Approval

By October 23, 2018

Khapzory will be supplied in single-dose vials containing 175mg and 300mg of levoleucovorin lyophilized powder for reconstitution before intravenous administration.

Treatment for Rare Pediatric Cancer Granted Orphan Drug Designation

By May 10, 2018

CLR 131 is an investigational radioiodinated Phospholipid Drug Conjugate (PDC) drug candidate that delivers cytotoxic radiation directly and selectively to malignant cells.

Adipocytes May Clear Daunorubicin, Contribute to Poorer Survival Outcomes

November 09, 2017

The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies.

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

ANDA Accepted for Generic Doxil Injection

By October 31, 2016

Merrimack announced that the FDA has accepted for review the ANDA for generic Doxorubicin Hydrochloride (HCI) Liposome Injection.

Lartruvo Approved for Soft Tissue Sarcoma

By October 20, 2016

The Food and Drug Administration has granted accelerated approval to Lartruvo (olaratumab) injection with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).

Antifungal-Chemotherapy Drug Interaction Update

By September 13, 2016

The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.

Outcomes of Daratumumab Tx Examined in Relapsed Multiple Myeloma

August 25, 2016

Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in the August 25 issue of the New England Journal of Medicine.

FDA Approves Updated ONJ Warning for Prolia, Xgeva

By August 09, 2016

The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).

Receiving Myeloma Immunotherapy Earlier May Have Greater Efficacy

June 07, 2016

Daratumumab (Darzalex), a recently approved immunotherapy drug for multiple myeloma, can provide better benefits if patients receive it earlier in their treatment, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held in Chicago.

Radiation Benefits Superior for Older Patients With in Soft-Tissue Sarcoma

April 15, 2016

Older patients with soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, according to research published in Anticancer Research.

Unexpected Derm Diagnosis in Patient Treated with Dabrafenib

March 17, 2016

In a case report published online February 28 in the Journal of Clinical Pharmacy and Therapeutics, researchers document non-HIV-associated Kaposi sarcoma in a male patient with myasthenia gravis and metastatic melanoma treated with the BRAF inhibitor dabrafenib.

Cancer Deaths Declining by 1.5% a Year in the U.S.

March 10, 2016

Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.

Halaven Gains Expanded Use for Treatment of Liposarcoma

By January 28, 2016

The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy containing an anthracycline.

Pexidartinib Designated Breakthrough Therapy for Rare Tumor

By November 02, 2015

The FDA has granted Breakthrough Therapy designation to pexidartinib (formerly PLX3397; Daiichi Sankyo/Plexxikon) for the treatment of tenosynovial giant cell tumor (TGCT) where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.

Yondelis Approved for Advanced Soft Tissue Sarcoma

By October 23, 2015

The Food and Drug Administration (FDA) has approved Yondelis (trabectedin; Janssen) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

FDA Accepts sNDA for Soft Tissue Sarcoma Tx

By September 28, 2015

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for eribulin mesylate (Eisai) for the treatment of patients with inoperable soft tissue sarcoma (leiomyosarcoma and liposarcoma) who have received prior chemotherapy for advanced or metastatic disease.

Dactinomycin Nanoparticle Formulation Receives Orphan Drug Designation

By July 30, 2015

The Food and Drug Administration (FDA) has granted Orphan Drug designation to dactinomycin nanoparticle formulation (NanoSmart) for the treatment of Ewing's sarcoma.

Research Calls for Gene Tests in Cancer to Include Normal Tissue

April 16, 2015

If genetic tests are only done on cancer tissue, as many as half of patients may not receive the most appropriate treatment for their cancer, according to new research.

Eribulin vs. Dacarbazine for Soft Tissue Sarcoma: New Data Released

By February 25, 2015

Eisai announced results from a Phase 3 trial investigating the use of eribulin vs. dacarbazine in patients with advanced soft tissue sarcomas.

Cancer Risk With Eczema Drug Tracked in Long-Term Study

By February 19, 2015

Treatment with pimecrolimus for eczema was found unlikely to increase the risk of cancer in children, according to a post-marketing study.

ANA-Conjugated Liposomal Doxorubicin Designated Orphan Drug for Ewing's Sarcoma

By February 12, 2015

The Food and Drug Administration (FDA) has granted Orphan Drug designation to its antinuclear antibody (ANA) conjugated liposomal doxorubicin (NanoSmart Pharmaceuticals) intended to treat Ewing's sarcoma, with potential expansion to other indications.

Yondelis NDA Granted Priority Review for Soft Tissue Sarcoma

By February 03, 2015

Janssen R&D and PharmaMar announced that the Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for Yondelis (trabectedin).

Xgeva Gains Hypercalcemia of Malignancy Indication

December 08, 2014

Amgen announced that the Food and Drug Administration (FDA) has approved Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

Nearly 1 in 20 Cancer Patients Die Within Month of Surgery

October 16, 2014

In a study of more than 1.1 million cancer patients who had surgery, Harvard researchers found that almost 5% died within one month of their operation.

Targeted Cancer Drugs Among Successes, Says AACR

September 17, 2014

About 14.5 million U.S. cancer survivors are alive today, compared to just three million in 1971, with prevention and targeted therapies helping to reduce mortality.

Surgery for Spinal Metastasis Up From 2000-2009

August 29, 2014

From 2000-2009 there was an increase in surgical treatment for spinal metastasis in the United States, which was accompanied by increased complication rates and costs.

First 3D-Printed Vertebra Successfully Implanted

August 25, 2014

A 12-year-old boy with a spinal injury stemming from bone cancer has received the first 3-D printed vertebra over a five-hour operation.